Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0Y6WU)

• Drug Name: REGN5678 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM0Y6WU

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[3]
AB-103	DMPDQ8T	Necrotizing soft tissue infection	1B71	Phase 3	[4]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[5]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[6]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[7]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[8]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[9]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[10]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[11]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[12]

Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capromab	DMHERIJ	Prostate cancer	2C82.0	Approved	[13]
PSMA-11 Ga-68	DMWLTU2	Diagnostic imaging	N.A.	Approved	[14]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Prostate cancer	2C82.0	Approved	[15]
177-Lu-PSMA-617	DMX178V	Prostate cancer	2C82.0	Phase 3	[16]
BAY 2315497	DMUHH2G	Prostate cancer	2C82.0	Phase 3	[17]
J 591 Lu-177	DM9XKJU	Prostate cancer	2C82.0	Phase 2	[18]
G-202	DMQR9I8	Adenocarcinoma	2D40	Phase 2	[19]
ATL101	DMYAQV2	Influenza virus infection	1E30-1E32	Phase 2	[20]
99mTc-MIP-1404	DML4GU1	Prostate cancer	2C82.0	Phase 2	[21]
MLN-591RL	DMJHVZC	Prostate cancer	2C82.0	Phase 2	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Inhibitor	[2]
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03972657) Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [3] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Sanofi.
• [9] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [10] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [11] Clinical pipeline report, company report or official report of Genentch
• [12] Clinical pipeline report, company report or official report of Roche
• [13] Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
• [16] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
• [17] ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [18] Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
• [19] National Cancer Institute Drug Dictionary (drug id 666090).
• [20] Clinical pipeline report, company report or official report of Atlab pharma.
• [21] 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
• [22] Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.